JP5933746B2 - イミダゾリジンジオン系化合物およびその用途 - Google Patents

イミダゾリジンジオン系化合物およびその用途 Download PDF

Info

Publication number
JP5933746B2
JP5933746B2 JP2014546301A JP2014546301A JP5933746B2 JP 5933746 B2 JP5933746 B2 JP 5933746B2 JP 2014546301 A JP2014546301 A JP 2014546301A JP 2014546301 A JP2014546301 A JP 2014546301A JP 5933746 B2 JP5933746 B2 JP 5933746B2
Authority
JP
Japan
Prior art keywords
compound
deuterated
group
mmol
hydrogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2014546301A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015501820A (ja
JP2015501820A5 (enExample
Inventor
チェン，ユアンウェイ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hc Pharmaceutical Co Ltd
Original Assignee
Hc Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hc Pharmaceutical Co Ltd filed Critical Hc Pharmaceutical Co Ltd
Publication of JP2015501820A publication Critical patent/JP2015501820A/ja
Publication of JP2015501820A5 publication Critical patent/JP2015501820A5/ja
Application granted granted Critical
Publication of JP5933746B2 publication Critical patent/JP5933746B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/08—Antiseborrheics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/28—Antiandrogens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/72—Two oxygen atoms, e.g. hydantoin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/86—Oxygen and sulfur atoms, e.g. thiohydantoin

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2014546301A 2011-12-14 2012-12-13 イミダゾリジンジオン系化合物およびその用途 Active JP5933746B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2011104188590A CN103159680A (zh) 2011-12-14 2011-12-14 咪唑二酮类化合物及其用途
CN201110418859.0 2011-12-14
PCT/CN2012/086573 WO2013087004A1 (zh) 2011-12-14 2012-12-13 咪唑二酮类化合物及其用途

Publications (3)

Publication Number Publication Date
JP2015501820A JP2015501820A (ja) 2015-01-19
JP2015501820A5 JP2015501820A5 (enExample) 2015-04-23
JP5933746B2 true JP5933746B2 (ja) 2016-06-15

Family

ID=48583248

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014546301A Active JP5933746B2 (ja) 2011-12-14 2012-12-13 イミダゾリジンジオン系化合物およびその用途

Country Status (9)

Country Link
US (1) US9346764B2 (enExample)
EP (1) EP2792674B1 (enExample)
JP (1) JP5933746B2 (enExample)
CN (2) CN103159680A (enExample)
AU (1) AU2012350482B2 (enExample)
CA (1) CA2859224C (enExample)
ES (1) ES2587903T3 (enExample)
PL (1) PL2792674T3 (enExample)
WO (1) WO2013087004A1 (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3020714B1 (en) * 2013-05-29 2022-12-28 Hinova Pharmaceuticals Inc. Imidazole diketone compound and use thereof
RU2016110546A (ru) * 2013-09-19 2017-10-24 ГЛАКСОСМИТКЛАЙН ЭлЭлСи Комбинированная лекарственная терапия
CN106543085A (zh) * 2013-10-14 2017-03-29 杭州普晒医药科技有限公司 恩杂鲁胺的固态形式及其制备方法和用途
CN104803919A (zh) * 2014-01-26 2015-07-29 上海医药工业研究院 用于制备恩杂鲁胺中间体的方法
WO2016051423A2 (en) * 2014-10-01 2016-04-07 Laurus Labs Private Limited An improved process for the preparation of enzalutamide
CN106432090B (zh) * 2015-10-30 2019-08-20 成都海创药业有限公司 一种氘代咪唑酮化合物的晶型及其制备方法和用途
CN107303278B (zh) * 2016-04-25 2020-11-13 成都海创药业有限公司 一种hc-1119固体分散体及其制备方法
CN107954936B (zh) * 2016-10-17 2021-03-19 海创药业股份有限公司 一种制备氘代咪唑二酮类化合物的方法
KR102125661B1 (ko) 2017-02-13 2020-06-22 강푸 바이오파마슈티칼즈 리미티드 전립선암 치료용 조합, 약학 조성물 및 치료 방법
WO2019025250A1 (en) 2017-08-04 2019-02-07 Basf Se SUBSTITUTED TRIFLUOROMETHYLOXADIAZOLES FOR COMBATING PHYTOPATHOGENIC FUNGI
CA3095221A1 (en) * 2018-03-29 2019-10-03 Hinova Pharmaceuticals Inc. Deuterated imidazolidinedione compounds and their uses
JP2021521190A (ja) * 2018-04-13 2021-08-26 ヒノバ ファーマシューティカルズ インコーポレイテッド 重水素化アミド及び重水素化スルホンアミドを合成する新規な方法
AU2019268481B2 (en) * 2018-05-14 2025-04-03 Hinova Pharmaceuticals Inc. HC-1119 formulation, preparation method and use thereof
WO2020095183A1 (en) 2018-11-05 2020-05-14 Pfizer Inc. Combination for treating cancer
CN112442009B (zh) * 2019-08-30 2023-10-03 润佳（苏州）医药科技有限公司 氘代化合物及其在治疗癌症方面的应用
CN115380026B (zh) * 2020-03-17 2023-11-07 南京明德新药研发有限公司 蛋白降解调节剂与其使用方法
CA3188821A1 (en) 2020-08-13 2022-02-17 Lars ANDERS Combination therapy
CN114181155A (zh) * 2021-12-21 2022-03-15 上海朝晖药业有限公司 碘-恩杂鲁胺及其制备方法及其应用
CN115181043B (zh) * 2022-07-27 2024-05-07 爱斯特（成都）生物制药股份有限公司 一种连续流制备4-异硫氰基-2-(三氟甲基)苯甲腈的方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101579701B1 (ko) * 2005-05-13 2015-12-22 더 리전트 오브 더 유니버시티 오브 캘리포니아 디아릴히단토인 화합물
DK2656842T3 (en) * 2006-03-27 2016-11-07 Univ California Androgen receptor MODULATOR FOR THE TREATMENT OF PROSTATE CANCER AND androgen receptor-ASSOCIATED DISEASES
EP3020706A1 (en) * 2006-03-29 2016-05-18 The Regents Of The University Of California Diarylthiohydantoin compounds useful for the treatment of a hyperproliferative disorder
CN101817787B (zh) * 2009-02-26 2013-07-24 童友之 抗前列腺癌的雄性激素受体拮抗剂
JP5659232B2 (ja) 2009-09-10 2015-01-28 トン、ヨウヂ アンドロゲン受容体アンタゴニストおよびその使用
WO2013067151A1 (en) * 2011-11-02 2013-05-10 Medivation Prostate Therapeutics, Inc. Treatment methods using diarylthiohydantoin derivatives

Also Published As

Publication number Publication date
EP2792674A4 (en) 2015-06-17
AU2012350482A1 (en) 2014-07-10
US9346764B2 (en) 2016-05-24
JP2015501820A (ja) 2015-01-19
CN103159680A (zh) 2013-06-19
CN104024228B (zh) 2015-07-08
WO2013087004A1 (zh) 2013-06-20
EP2792674A1 (en) 2014-10-22
AU2012350482B2 (en) 2017-02-16
US20140371284A1 (en) 2014-12-18
CN104024228A (zh) 2014-09-03
EP2792674B1 (en) 2016-05-25
CA2859224C (en) 2019-03-19
CA2859224A1 (en) 2013-06-20
HK1198166A1 (en) 2015-03-13
ES2587903T3 (es) 2016-10-27
PL2792674T3 (pl) 2016-12-30

Similar Documents

Publication Publication Date Title
JP5933746B2 (ja) イミダゾリジンジオン系化合物およびその用途
JP6469092B2 (ja) イミダゾリジンジオン化合物及び薬物組成物
KR100674813B1 (ko) Ｎ-페닐-2-피리미딘-아민 유도체 및 그의 제조방법
JP7720099B2 (ja) 免疫調節剤としてのビアリール環結合芳香族複素環誘導体の調製およびその適用
CN113563319A (zh) 具有磷酸二酯酶4b抑制活性的吲唑杂环类化合物
JP7665213B2 (ja) 三環系構造を有する芳香複素環式化合物、およびその調製方法と適用
KR101827660B1 (ko) 플루오로페닐 피라졸 화합물
CN113248474A (zh) 五元氮唑杂环衍生物及其制备方法和用途
CN119661432A (zh) 一种prmt5抑制剂及其药物组合物、药物制剂和用途
CN107739381B (zh) 莪术醇衍生物及其在制备抗肿瘤药物中的应用
CN114933601A (zh) 汉防己甲素衍生物及其制备方法和应用
JP2024518569A (ja) アルキルフェノール系化合物およびその製造方法
CN114831977A (zh) 苯甲酸类衍生物作为trpm2蛋白抑制剂的用途
KR102406248B1 (ko) Hsp90 억제제로서의 1,2,3-트리아졸 유도체 화합물
JP2579701B2 (ja) 新規キノリン誘導体およびそれを有効成分として含有する制癌剤効果増強剤
WO2024125662A1 (zh) 新型联芳环化合物作为免疫调节剂的制备和应用
KR20250053959A (ko) 퀴놀린 유도체 억제제의 결정형 및 이의 제조 방법과 용도
CN117946165A (zh) 一种新型结构化合物axl抑制剂及其应用
CN117986249A (zh) 吡唑类衍生物抑制剂、其制备方法和应用
CN120309546A (zh) 一种苯并咪唑-2-硫代乙酰胺的衍生物化合物及其制备方法和应用
CN119143734A (zh) 作为at2r拮抗剂的杂环化合物及其用途
HK1198166B (en) Imidazolidinedione compounds and their uses

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150305

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20150305

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20151022

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20151124

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20160224

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160324

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20160414

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20160502

R150 Certificate of patent or registration of utility model

Ref document number: 5933746

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

S531 Written request for registration of change of domicile

Free format text: JAPANESE INTERMEDIATE CODE: R313531

S533 Written request for registration of change of name

Free format text: JAPANESE INTERMEDIATE CODE: R313533

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

S531 Written request for registration of change of domicile

Free format text: JAPANESE INTERMEDIATE CODE: R313531

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250